What Precautions Should People with Gaucher Disease Take With COVID-19?
As of 12/22/2022. All information contained is provided with input from physicians on the NGF Medical Advisory Board.
Medical understanding of SARS-CoV-2, the coronavirus that causes COVID-19, is evolving. To maintain your optimal health, follow your local guidance and CDC COVID-19 recommendations.
A Word of Caution About COVID-19 Information
Any government agency or organization website—including this one—provides only general information. Not all of this information will apply to you. Your Gaucher specialist is the best person to advise you.
Every Gaucher patient needs an individualized care plan, not only for GD, but for all other concurrent illnesses, including COVID-19. Your treating physician can discuss your individual risk and tailor risk-reduction strategies to your needs.
You should continue all treatments and medical management of lysosomal disorders, including Gaucher disease. Before making any changes to your medical regimen, or if you need care for COVID-19-related illness, seek advice from both your Gaucher specialist and your primary care provider (PCP).
The FDA has approved two mRNA vaccines (Pfizer-BioNTech and Moderna) and issued an Emergency Use Authorization (EUA) for one protein subunit vaccine (Novavax) as well as one modified adenovirus vaccine (Johnson & Johnson Janssen). The CDC Interim Clinical Considerations indicate that the vaccines may be administered to persons with underlying medical conditions who have no contraindications to vaccination.
A panel of Gaucher specialists from Gaucher treatment centers have addressed the many questions regarding the new COVID-19 vaccines.
